Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2 monoclonal antibody BAT1006

A glycosylation engineered recombinant humanized monoclonal antibody targeting the extracellular dimerization domain (subdomain II) of the tumor-associated antigen (TAA) and tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody BAT1006 targets and binds to HER2 on tumor cells, thereby blocking HER2-mediated signaling. This may inhibit the proliferation of HER2-expressing tumor cells. In addition, BAT1006 induces antibody-dependent cell-mediated cytotoxicity (ADCC). HER2, overexpressed on a variety of tumor cell types, plays an important role in tumor cell proliferation, differentiation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BAT 1006
BAT-1006
BAT1006
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search